The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma
2024
The Neuroprotective Role of A2A Adenosine Purinoceptor Modulation as a Strategy Against Glioblastoma
publication
Evidence: moderate
Author Information
Author(s): Simões Júlia Leão Batista, Braga Geórgia de Carvalho, Fontana Michelli, Assmann Charles Elias, Bagatini Margarete Dulce
Primary Institution: Federal University of Fronteira Sul
Hypothesis
Can the inhibition of A2A receptors serve as a potential therapy for glioblastoma using Istradefylline?
Conclusion
Istradefylline shows promise as a potential treatment for glioblastoma by inhibiting A2A receptors, which may enhance the effectiveness of existing therapies.
Supporting Evidence
- Istradefylline has been approved for treating Parkinson's disease and shows potential as an antineoplastic drug.
- Blocking A2A receptors may enhance the immune response against glioblastoma.
- Current treatments for glioblastoma have limited effectiveness, highlighting the need for new therapies.
- Adenosine receptors are involved in tumor progression and immune evasion in glioblastoma.
Takeaway
This study looks at a drug called Istradefylline that might help treat a dangerous brain cancer by blocking certain receptors in the brain.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website